GlassScriptPhysician profile
Cedricka Lavender
NPI 1477259737
$2,685.39
in general payments reported to CMS, 2019-2025
20 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $655 · 2024: $722 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.40 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $560.00 | 2023-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $253.98 | 2024-2025 | |
| Insmed, INC. | $232.03 | 2023-2025 | Arikayce, Brinsupri |
| Amgen INC. | $199.86 | 2023-2025 | Tezspire |
| Glaxosmithkline, LLC. | $197.02 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.73 | 2023-2025 | Ofev |
| Pulmonx Corporation | $167.95 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Grifols USA, LLC | $152.12 | 2023-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $102.85 | 2023-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $101.40 | 2024-2025 | Dupixent |
| Baxter Healthcare | $90.00 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $80.77 | 2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Merck Sharp & Dohme LLC | $76.88 | 2023-2025 | Winrevair |
| Viatris Specialty LLC | $58.13 | 2025 | Yupelri |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $44.19 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $42.59 | 2024-2025 | Acthar |
| Harmony Biosciences LLC | $37.38 | 2025 | |
| Lilly USA, LLC | $15.29 | 2025 | Zepbound |
| Ani Pharmaceuticals, INC. | $15.23 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cedricka Lavender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.